Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin—In Reply

In Reply We thank Chien and colleagues for their interest in our study of aspirin use and incident hepatocellular carcinoma (HCC) in the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.¹ The authors argue that a disproportionate number of the patients with HCC were women; however, the number of cases reflects our underlying population, which was composed of 87 507 women (Nurses’ Health Study) and 45 864 men (Health Professionals Follow-up Study). Indeed, our sex-specific cumulative incidence of HCC was 2 per 100 000 women and 5 per 100 000 men, which corresponds to population-based estimates for the time period of our study (1980-2012 in women; 1986-2012 in men).²